IL6 and atherosclerosis: In vitro results have shown that trelagliptin treatment inhibited the expression of MCP-1, CXCL-1, IL-6, VCAM-1, and ICAM-1 in human aortic endothelial cells exposed to IL-1β, mimicking the microenvironment of atherosclerosis.